- Home
- UGRO vs PPBT Comparison
UGRO vs PPBT Comparison
Compare UGRO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- PPBT
- Stock Information
- Founded
- UGRO 2014
- PPBT 2010
- Country
- UGRO United States
- PPBT Israel
- Employees
- UGRO N/A
- PPBT N/A
- Industry
- UGRO Industrial Specialties
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- PPBT Health Care
- Exchange
- UGRO Nasdaq
- PPBT Nasdaq
- Market Cap
- UGRO 8.8M
- PPBT 7.1M
- IPO Year
- UGRO N/A
- PPBT N/A
- Fundamental
- Price
- UGRO $0.45
- PPBT $2.78
- Analyst Decision
- UGRO Strong Buy
- PPBT Strong Buy
- Analyst Count
- UGRO 2
- PPBT 1
- Target Price
- UGRO $3.13
- PPBT $33.00
- AVG Volume (30 Days)
- UGRO 101.1K
- PPBT 13.2K
- Earning Date
- UGRO 04-29-2025
- PPBT 03-10-2025
- Dividend Yield
- UGRO N/A
- PPBT N/A
- EPS Growth
- UGRO N/A
- PPBT N/A
- EPS
- UGRO N/A
- PPBT N/A
- Revenue
- UGRO $59,985,133.00
- PPBT N/A
- Revenue This Year
- UGRO $2.17
- PPBT N/A
- Revenue Next Year
- UGRO $27.19
- PPBT N/A
- P/E Ratio
- UGRO N/A
- PPBT N/A
- Revenue Growth
- UGRO N/A
- PPBT N/A
- 52 Week Low
- UGRO $0.38
- PPBT $2.00
- 52 Week High
- UGRO $2.16
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- UGRO 17.79
- PPBT 45.85
- Support Level
- UGRO $0.45
- PPBT $2.64
- Resistance Level
- UGRO $0.62
- PPBT $2.93
- Average True Range (ATR)
- UGRO 0.07
- PPBT 0.15
- MACD
- UGRO -0.03
- PPBT 0.03
- Stochastic Oscillator
- UGRO 15.39
- PPBT 33.05
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.